Want to see XBIO full AI Analyst Report?
XBIO Stock Chart & Stats
$2.21
-$0.03(-0.75%)
At close: 4:00 PM EST
$2.21
-$0.03(-0.75%)
Day’s Range― - ―
52-Week Range$1.90 - $13.93
Previous CloseN/A
Volume4.73K
Average Volume (3M)1.70M
Market Cap
$6.36M
Enterprise Value-$1.66M
Total Cash (Recent Filing)$7.35M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding2,291,056
10 Day Avg. Volume5,053,508
30 Day Avg. Volume1,695,238
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.50
Price to Sales (P/S)1.24
P/FCF Ratio-1.61
Enterprise Value/Market Cap-0.26
Enterprise Value/Revenue-0.52
Enterprise Value/Gross Profit-0.52
Enterprise Value/Ebitda0.74
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.32
Revenue Forecast (FY)$3.00M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt and positive equity provide durable financial flexibility, reducing near-term refinancing risk and preserving optionality for licensing, partnerships, or targeted R&D spend. A debt-free structure supports strategic choices without immediate interest burdens.
High Gross MarginsSustained ~75% gross margin indicates structural product/service economics that can support long-term profitability if operating leverage is achieved. High gross margins give the company room to invest in R&D and commercialization without eroding unit economics.
Revenue Growth TrendConsistent TTM revenue growth demonstrates improving commercial traction or licensing activity, which can lengthen runway and attract partners. Continued top-line expansion supports future margin improvement and reduces reliance on external funding.
Bears Say
Sustained UnprofitabilityDeep, persistent negative margins signal that current operations are not self-sustaining and that material change is required to reach break-even. Ongoing losses erode shareholder value and limit ability to self-fund growth without external capital or meaningful cost restructuring.
Negative Operating Cash FlowConsistent negative operating and free cash flow create persistent funding needs. This raises dilution or financing risk, constrains discretionary R&D or commercialization spending, and makes long-term plans contingent on new capital or partner transactions.
Erosion Of Shareholder EquityMaterial decline in equity reflects cumulative losses and reduces the balance-sheet buffer to absorb future setbacks. With depleted equity, the company is more vulnerable to dilution when raising capital and has less cushion to absorb R&D missteps or trial setbacks.
Xenetic Biosciences News
XBIO FAQ
What was Xenetic Biosciences’s price range in the past 12 months?
Xenetic Biosciences lowest stock price was $1.90 and its highest was $13.93 in the past 12 months.
What is Xenetic Biosciences’s market cap?
Xenetic Biosciences’s market cap is $6.36M.
When is Xenetic Biosciences’s upcoming earnings report date?
Xenetic Biosciences’s upcoming earnings report date is Aug 07, 2026 which is in 27 days.
How were Xenetic Biosciences’s earnings last quarter?
Xenetic Biosciences released its earnings results on May 13, 2026. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.2.
Is Xenetic Biosciences overvalued?
According to Wall Street analysts Xenetic Biosciences’s price is currently Overvalued.
Does Xenetic Biosciences pay dividends?
Xenetic Biosciences does not currently pay dividends.
What is Xenetic Biosciences’s EPS estimate?
Xenetic Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xenetic Biosciences have?
Xenetic Biosciences has 2,291,056 shares outstanding.
What happened to Xenetic Biosciences’s price movement after its last earnings report?
Xenetic Biosciences reported an EPS of -$0.2 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.159%.
Which hedge fund is a major shareholder of Xenetic Biosciences?
Currently, no hedge funds are holding shares in XBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xenetic Biosciences
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.
Technical Analysis
Ownership Overview
4.36% Insiders
0.87% Mutual Funds
0.12% Other Institutional Investors
94.09% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---